SavedAdd your journal

Journals / Journal of Medical Topics and Updates / 2026 / Cilt: 5 Sayı: 2

Nutritional Risk During GLP-1-Based Obesity Treatment: Preservation of Lean Mass, Inadequate Micronutrient Intake and Dietetic Monitoring

GLP-1 Temelli Obezite Tedavilerinde Beslenme Riski: Yağsız Kütlenin Korunması, Mikro Besin Ögesi Alım Yetersizlikleri ve Diyetetik İzlem

Hasan Kaan Kavsara(Yeditepe University)0000-0002-0322-0397
Pages
41–48
Publication Date
2026-09-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Individualized nutrition support, resistance exercise, and regular dietetic follow-up should be integrated into treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Glucagon-like peptide-1 (GLP-1)-based therapies produce substantial weight loss in obesity management; however, reductions in appetite and food intake may increase the risks of inadequate protein and micronutrient intake, gastrointestinal intolerance, and loss of lean mass.
📊
Key Findings & Data:This review aimed to evaluate nutritional risks during GLP-1-based obesity treatment, examine evidence on lean mass and muscle health, and provide a framework for dietetic monitoring.
💡
Conclusion & Impact:Individualized nutrition support, resistance exercise, and regular dietetic follow-up should be integrated into treatment.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Glukagon benzeri peptid-1 reseptör agonistleri · obezite · vücut bileşimi

Abstract

Objective: Glucagon-like peptide-1 (GLP-1)-based therapies produce substantial weight loss in obesity management; however, reductions in appetite and food intake may increase the risks of inadequate protein and micronutrient intake, gastrointestinal intolerance, and loss of lean mass. This review aimed to evaluate nutritional risks during GLP-1-based obesity treatment, examine evidence on lean mass and muscle health, and provide a framework for dietetic monitoring. Materials and Methods: PubMed/MEDLINE, Web of Science Core Collection, and Scopus were searched using terms related to GLP-1 receptor agonists, semaglutide, liraglutide, tirzepatide, appetite, energy and nutrient intake, body composition, lean mass, skeletal muscle, sarcopenia, protein, resistance exercise, and dietetic monitoring. Randomized controlled trials in humans, observational studies, systematic reviews and meta-analyses were prioritized. Results: GLP-1-based therapies reduce hunger, food cravings, and energy intake while improving satiety and control of eating. Nevertheless, lower food intake and gastrointestinal adverse effects may compromise the intake of protein, fluids, fiber, and several micronutrients. Although reductions in lean mass occur alongside fat loss, they do not directly indicate skeletal muscle loss or sarcopenia. Changes in muscle quantity should be interpreted together with muscle quality, strength, and physical function. Older age, frailty, low baseline muscle reserve, physical inactivity, and inadequate protein intake appear to increase risk. Conclusion: Treatment success should not be evaluated solely by weight loss. Nutritional adequacy, gastrointestinal tolerance, body composition, muscle strength, and physical function should be monitored together. Individualized nutrition support, resistance exercise, and regular dietetic follow-up should be integrated into treatment.

Özet

Amaç: Glukagon benzeri peptid-1 (GLP-1) temelli tedaviler obezite yönetiminde belirgin ağırlık kaybı sağlamakla birlikte, iştah ve besin alımındaki azalma; yetersiz protein ve mikro besin ögesi alımı, gastrointestinal tolerans sorunları ve yağsız kütle kaybı açısından klinik kaygılar oluşturmaktadır. Bu derlemenin amacı, GLP-1 temelli obezite tedavilerinde beslenme risklerini değerlendirmek, yağsız kütle ve kas sağlığına ilişkin kanıtları incelemek ve diyetetik izleme yönelik bir çerçeve sunmaktır. Materyal ve Metot: PubMed/MEDLINE, Web of Science Core Collection ve Scopus veri tabanlarında GLP-1 reseptör agonistleri, semaglutid, liraglutid, tirzepatid, iştah, enerji ve besin ögesi alımı, vücut kompozisyonu, yağsız kütle, iskelet kası, sarkopeni, protein, direnç egzersizi ve diyetetik izlem ile ilişkili terimler kullanılarak anlatı derlemesi yapılmıştır. İnsanlarda yürütülen randomize kontrollü çalışmalar, gözlemsel araştırmalar, sistematik derlemeler ve meta-analizler öncelikli olarak değerlendirilmiştir. Bulgular: GLP-1 temelli tedaviler açlık, besin isteği ve enerji alımını azaltırken tokluk ve yeme kontrolünü artırmaktadır. Bununla birlikte azalan besin tüketimi ve gastrointestinal yan etkiler, protein, sıvı, lif ve bazı mikro besin ögelerinin yetersiz alınmasına yol açabilmektedir. Yağ kütlesiyle birlikte yağsız kütlede de azalma bildirilmesine karşın, bu değişim doğrudan iskelet kası kaybı veya sarkopeni anlamına gelmemektedir. Kas miktarı; kas kalitesi, kas gücü ve fiziksel işlevle birlikte değerlendirilmelidir. İleri yaş, kırılganlık, düşük kas rezervi, fiziksel inaktivite ve yetersiz protein alımı daha yüksek riskle ilişkilidir. Sonuç: Tedavi başarısı yalnızca ağırlık kaybıyla değerlendirilmemelidir. Beslenme yeterliliği, gastrointestinal tolerans, vücut kompozisyonu, kas gücü ve fiziksel işlev birlikte izlenmeli; bireyselleştirilmiş beslenme desteği, direnç egzersizi ve düzenli diyetetik izlem tedaviye entegre edilmelidir.

🔖

Cite This Article

Kavsara, H. K. (2026). Nutritional Risk During GLP-1-Based Obesity Treatment: Preservation of Lean Mass, Inadequate Micronutrient Intake and Dietetic Monitoring. Journal of Medical Topics and Updates, Cilt: 5 Sayı: 2, 41–48. https://doi.org/10.58651/jomtu.1980569

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (27)

  1. Jensen SBK, Blond MB, Sandsdal RM, Olsen LM, Juhl CR, Lundgren JR, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine [Internet]. 2024; 69:102475. Available from: https://linkinghub.elsevier.com/retrieve/pii/ S2589537024000543.
  2. Old VJ, Davies MJ, Papamargaritis D, Choudhary P, Watson EL. The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review. J Cachexia Sarcopenia Muscle [Internet]. 2025; 16(1). Available from: https://onlinelibrary.wiley.com/ doi/10.1002/jcsm.13677.
  3. Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes [Internet]. 2025; 49(3):433–51. Available from: https://www.nature.com/articles/s41366-024-01473-y.
  4. Ryan DH. New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? Rev Endocr Metab Disord [Internet]. 2025; 26(5):805–13. Available from: https://link.springer.com/10.1007/s11154-025-09967-4.
  5. Wadden TA, Chao AM, Moore M, Tronieri JS, Gilden A, Amaro A, et al. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Curr Obes Rep [Internet]. 2023; 12(4):453–73. Available from: https://link.springer.com/10.1007/ s13679-023-00534-z.
  6. Gigliotti L, Warshaw H, Evert A, Dawkins C, Schwartz J, Susie C, et al. Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care. J Acad Nutr Diet [Internet]. 2025; 125(3):408–21. Available from: https://linkinghub.elsevier.com/retrieve/ pii/S2212267224009250.
  7. Kadowaki T, Kiyosue A, Shingaki T, Oura T, Yokote K. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol [Internet]. 2025; 13(5):384–96. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2213858724003772.
  8. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab [Internet]. 2021; 23(3):754–62. Available from: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14280.
  9. Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab [Internet]. 2017; 19(9):1242–51. Available from: https://dom-pubs.pericles-prod. literatumonline.com/doi/10.1111/dom.12932.
  10. Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr [Internet]. 2025; 122(1):344–67. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002916525002400.
  11. Johnson B, Milstead M, Thomas O, McGlasson T, Green L, Kreider R, et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Front Nutr [Internet]. 2025; 12. Available from: https://www.frontiersin.org/articles/10.3389/fnut.2025.1566498/full.
  12. Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al. Nutritional priorities to support GLP‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity [Internet]. 2025; 33(8):1475–503. Available from: https://onlinelibrary. wiley.com/doi/10.1002/oby.24336.
  13. Hubert PA, Coleman C, Grosicki GJ, Kiel J, Shepherd M, Lofton HF, et al. Mind the Plateau: A Mathematical Modeling Analysis of Long-Term GLP-1 Receptor Agonist Treatment. J Acad Nutr Diet [Internet]. 2026; 126(8):156366. Available from: https://linkinghub.elsevier.com/retrieve/pii/ S221226722600081X.
  14. Caturano A, Amaro A, Berra CC, Conte C. Sarcopenic obesity and weight loss-induced muscle mass loss. Curr Opin Clin Nutr Metab Care [Internet]. 2025; 28(4):339–50. Available from: https://journals.lww.com/10.1097/ MCO.0000000000001131.
  15. Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism [Internet]. 2025; 164:156113. Available from: https://linkinghub.elsevier.com/retrieve/pii/ S002604952400341X.
  16. Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care [Internet]. 2024; 47(10):1718– 30. Available from: https://diabetesjournals.org/care/article/47/10/1718/154535/ Incretin-Based-Weight-Loss-Pharmacotherapy-Can.
  17. Mechanick JI, Butsch WS, Christensen SM, Hamdy O, Li Z, Prado CM, et al. Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity. Obesity Reviews [Internet]. 2025; 26(1). Available from: https://onlinelibrary.wiley.com/doi/10.1111/obr.13841.
  18. Linge J, Birkenfeld AL, Neeland IJ. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation [Internet]. 2024; 150(16):1288–98. Available from: https://www. ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.067676.
  19. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies. Diabetes Obes Metab [Internet]. 2024; 26(S4):16–27. Available from: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15728.
  20. Memel Z, Gold SL, Pearlman M, Muratore A, Martindale R. Impact of GLP1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia. Curr Nutr Rep [Internet]. 2025; 14(1):63. Available from: https://link.springer.com/10.1007/ s13668-025-00649-w.
  21. Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care [Internet]. 2023; 46(5):998–1004. Available from: https://diabetesjournals.org/care/article/46/5/998/148546/Tirzepatide-Reduces-Appetite-Energy-Intake-and-Fat.
  22. Badulescu S, Tabassum A, Le GH, Wong S, Phan L, Gill H, et al. Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review. Physiol Behav [Internet]. 2024; 283:114622. Available from: https://linkinghub. elsevier.com/retrieve/pii/S0031938424001677.
  23. Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care [Internet]. 2024; 47(11):1873–88. Available from: https://diabetesjournals.org/care/article/47/11/1873/156807/Efficacy-and-Safety-of-GLP-1-Medicines-for-Type-2.
  24. Reiss AB, Gulkarov S, Lau R, Klek SP, Srivastava A, Renna HA, et al. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules [Internet]. 2025; 15(3):408. Available from: https://www.mdpi.com/2218-273X/15/3/408.
  25. Jalleh RJ, Plummer MP, Marathe CS, Umapathysivam MM, Quast DR, Rayner CK, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab [Internet]. 2024; 110(1):1–15. Available from: https://academic.oup.com/jcem/article/110/1/1/7824836.
  26. Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT‐1 study of adults with obesity or overweight. Diabetes Obes Metab [Internet]. 2025; 27(5):2720–9. Available from: https://dom-pubs.pericles-prod. literatumonline.com/doi/10.1111/dom.16275.
  27. Pandey A, Patel K V., Segar MW, Ayers C, Linge J, Leinhard OD, et al. Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial. J Cachexia Sarcopenia Muscle [Internet]. 2024; 15(3):1072–83. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jcsm.13445.